Joel D. Allen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joel D. Allen has a total of 959 co-authors. Here are the top co-authors by number of shared publications:
- Max Crispin
University of Southampton
80 shared publications - Andrew B. Ward
Scripps Research Institute
37 shared publications - Rogier W. Sanders
Department of Medical Microbiology and Infection Prevention, Amsterdam UMC
18 shared publications - Christopher A. Cottrell
Department of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA
15 shared publications - Gabriel Ozorowski
Scripps Research Institute
14 shared publications - Yasunori Watanabe
School of Biological Sciences, University of Southampton, Southampton SO17 1BJ, U.K.
14 shared publications
Latest Publications
- Open Access
- 19 November 2026
- Published by Springer Nature in Research Square
Germline-targeting elicits cross-neutralizing, H3-dominated HIV CD4bs antibodies
Eliciting broadly neutralizing antibodies (bnAbs) remains central in HIV vaccine design, yet vaccines have not induced bnAbs in humans and have had limited success in animal models. A key challenge is converting precursor B-cell recognition into maturation toward conserved epitopes on HIV Env. Here, we show that a three-shot germline-targeting regimen reproducibly activates and matures CDRH3-dominated CD4-binding-site (CD4bs) antibody precursors in CH103-lineage knock-in mice, inducing strong autologous tier-2 and selected heterologous cross-neutralizing serum responses, as well as monoclonal antibodies with tier-2 cross-neutralizing activity. This response is enabled by native-like, membrane-embedded Env arrays on liposomes bearing limited germline-targeting mutations, including the N197D glycan-site mutation, that promote B-cell activation, CH103-class somatic hypermutation, and quaternary Env-antibody recognition. Cryo-electron microscopy of representative antibodies shows recognition of a quaternary CD4bs epitope involving adjacent Env protomers, linking serum neutralization to structural maturation. Env variants that bind multiple CD4bs precursor classes further point to a membrane-Env strategy for multi-lineage germline targeting.
- 19 November 2026
- Published by Springer Nature in Research Square
Open AccessGermline-targeting elicits cross-neutralizing, H3-dominated HIV CD4bs antibodies
Eliciting broadly neutralizing antibodies (bnAbs) remains central in HIV vaccine design, yet vaccines have not induced bnAbs in humans and have had limited success in animal models. A key challenge is converting precursor B-cell recognition into maturation toward conserved epitopes on HIV Env. Here, we show that a three-shot germline-targeting regimen reproducibly activates and matures CDRH3-dominated CD4-binding-site (CD4bs) antibody precursors in CH103-lineage knock-in mice, inducing strong autologous tier-2 and selected heterologous cross-neutralizing serum responses, as well as monoclonal antibodies with tier-2 cross-neutralizing activity. This response is enabled by native-like, membrane-embedded Env arrays on liposomes bearing limited germline-targeting mutations, including the N197D glycan-site mutation, that promote B-cell activation, CH103-class somatic hypermutation, and quaternary Env-antibody recognition. Cryo-electron microscopy of representative antibodies shows recognition of a quaternary CD4bs epitope involving adjacent Env protomers, linking serum neutralization to structural maturation. Env variants that bind multiple CD4bs precursor classes further point to a membrane-Env strategy for multi-lineage germline targeting.
- Open Access
Biomolecular design through latent reasoning with RFD4-Proteina
Biomolecular design requires finding chemically and geometrically compatible arrangements of interacting atoms and molecules. The complexity of problems which can be tackled by deep learning design models is limited by both the molecular landscape they encompass and their ability to explore that landscape effectively. Here we introduce RFD4-Proteina, which addresses these limitations through intrinsic and extrinsic reasoning within a shared chemical and conformational latent space. The latent space encompasses standard and modified amino acids, sugars, DNA, and RNA, with force-field supervision favoring physically plausible atomic reconstructions. Within this space, intrinsic reasoning uses recurrent refinement to adaptively allocate computation, while extrinsic reasoning guides search with arbitrary constraints such as energetic or geometric criteria. Across in silico protein design benchmarks, RFD4-Proteina achieves higher design success rates at greater generation throughput than all previous methods evaluated, with further gains from conformational flexibility, recurrent refinement, and search. The same model performs equivalently to or better than state-of-the-art specialist methods for side-chain packing, sequence design, conformational sampling, and design refinement. We demonstrate the power and versatility of RFD4-Proteina experimentally by designing specific and cross-reactive binders to therapeutically relevant targets, recognizing phosphorylations, controlling glycosylation, and creating enzymes that catalyze both bond-breaking and bond-forming reactions, including a first proof-of-concept demonstration of a de novo designed enzyme for active pharmaceutical ingredient synthesis. By unifying diverse chemistry, conformational flexibility, and scalable reasoning in a single physically grounded latent space, RFD4-Proteina expands the frontier of biomolecular design.
Open AccessBiomolecular design through latent reasoning with RFD4-Proteina
Biomolecular design requires finding chemically and geometrically compatible arrangements of interacting atoms and molecules. The complexity of problems which can be tackled by deep learning design models is limited by both the molecular landscape they encompass and their ability to explore that landscape effectively. Here we introduce RFD4-Proteina, which addresses these limitations through intrinsic and extrinsic reasoning within a shared chemical and conformational latent space. The latent space encompasses standard and modified amino acids, sugars, DNA, and RNA, with force-field supervision favoring physically plausible atomic reconstructions. Within this space, intrinsic reasoning uses recurrent refinement to adaptively allocate computation, while extrinsic reasoning guides search with arbitrary constraints such as energetic or geometric criteria. Across in silico protein design benchmarks, RFD4-Proteina achieves higher design success rates at greater generation throughput than all previous methods evaluated, with further gains from conformational flexibility, recurrent refinement, and search. The same model performs equivalently to or better than state-of-the-art specialist methods for side-chain packing, sequence design, conformational sampling, and design refinement. We demonstrate the power and versatility of RFD4-Proteina experimentally by designing specific and cross-reactive binders to therapeutically relevant targets, recognizing phosphorylations, controlling glycosylation, and creating enzymes that catalyze both bond-breaking and bond-forming reactions, including a first proof-of-concept demonstration of a de novo designed enzyme for active pharmaceutical ingredient synthesis. By unifying diverse chemistry, conformational flexibility, and scalable reasoning in a single physically grounded latent space, RFD4-Proteina expands the frontier of biomolecular design.
- 21 October 2026
- Published by Wiley in Biotechnology and Bioengineering
Translating Innovation to Clinic: End‐to‐End Bioprocess Development and cGMP Manufacturing of N332‐GT5 HIV Vaccine Candidate for First‐In‐Human Trials (HVTN144)
The successful translation of rationally designed HIV‐1 immunogens into effective vaccines requires manufacturing platforms that maintain structural conformity while meeting clinical‐grade quality standards. We developed and scaled up a robust, cGMP‐compliant process for N332‐GT5 gp140, a germline‐targeting envelope trimer designed to initiate broadly neutralizing antibody responses, which is now undergoing first‐in‐human evaluation in HVTN144. Starting with a stable CHO cell line developed using Leap‐In® transposon technology, we established a production clone exhibiting high‐titer expression (> 200 mg/L) and genetic stability through 60 population doublings. The manufacturing process scaled up efficiently from Ambr® 250 miniature bioreactors to 200‐L single‐use systems, delivering consistent product quality across multiple cGMP batches. A streamlined three‐step purification strategy—affinity capture, multimodal polishing, and viral clearance —yielded > 99% trimeric purity while preserving quaternary structure and native‐like antigenicity. Orthogonal LC‐MS analyses confirmed site‐specific glycan occupancy matching design specifications, while robust viral clearance exceeded 18‐log and 11‐log reductions for model retroviruses. Clinical material manufactured through this platform has been successfully administered in clinical trial HVTN144. This work establishes a scalable, reproducible manufacturing paradigm for structurally complex HIV‐1 envelope immunogens, advancing the field toward rational vaccine design based on germline‐targeting principles.
- 21 October 2026
- Published by Wiley in Biotechnology and Bioengineering
Translating Innovation to Clinic: End‐to‐End Bioprocess Development and cGMP Manufacturing of N332‐GT5 HIV Vaccine Candidate for First‐In‐Human Trials (HVTN144)
The successful translation of rationally designed HIV‐1 immunogens into effective vaccines requires manufacturing platforms that maintain structural conformity while meeting clinical‐grade quality standards. We developed and scaled up a robust, cGMP‐compliant process for N332‐GT5 gp140, a germline‐targeting envelope trimer designed to initiate broadly neutralizing antibody responses, which is now undergoing first‐in‐human evaluation in HVTN144. Starting with a stable CHO cell line developed using Leap‐In® transposon technology, we established a production clone exhibiting high‐titer expression (> 200 mg/L) and genetic stability through 60 population doublings. The manufacturing process scaled up efficiently from Ambr® 250 miniature bioreactors to 200‐L single‐use systems, delivering consistent product quality across multiple cGMP batches. A streamlined three‐step purification strategy—affinity capture, multimodal polishing, and viral clearance —yielded > 99% trimeric purity while preserving quaternary structure and native‐like antigenicity. Orthogonal LC‐MS analyses confirmed site‐specific glycan occupancy matching design specifications, while robust viral clearance exceeded 18‐log and 11‐log reductions for model retroviruses. Clinical material manufactured through this platform has been successfully administered in clinical trial HVTN144. This work establishes a scalable, reproducible manufacturing paradigm for structurally complex HIV‐1 envelope immunogens, advancing the field toward rational vaccine design based on germline‐targeting principles.
- Open Access
Xenoglycosylation of the HIV-1 Glycan Shield Promotes Cross-Clade Neutralization and Diverse Human Antibody Lineages
Despite advances in HIV-1 envelope glycoprotein (Env)-based vaccine design, eliciting broadly neutralizing antibodies (bNAbs) remains a central challenge. Here, we identify core α(1,3)-fucose as a key modulator of neutralizing antibody (NAb) induction and breadth. Uncleaved prefusion-optimized (UFO) trimers and self-assembling protein nanoparticles (SApNPs) produced in High Five (Hi5) insect cells incorporate core α(1,3)-fucose into the Env glycan shield. Crystal structures of Hi5-produced BG505 UFO trimers in complex with bNAbs confirm native-like Env architecture and epitope presentation. In wild-type mice, these trimers and SApNPs elicit robust autologous and heterologous NAb responses. We then engineer Chinese hamster ovary (CHO) cells to co-express three insect- and plant-derived core α(1,3)-fucosyltransferases. The resulting immunogens carry fucosylated mammalian glycans and elicit cross-clade NAb responses in mice, supporting an important role for core α(1,3)-fucose in broadened neutralization. Env-specific IgE responses suggest engagement of associated immune pathways during vaccination. In ATX-Gx humanized mice, core α(1,3)-fucosylated, glycan-trimmed Env elicits detectable cross-clade neutralization by week 11. Single-cell analysis identifies distinct human antibody lineages with cross-clade activity and noncanonical Env recognition. Repertoire and functional analyses uncover putatively related lineage members across two animals within the same group. Together, these findings support xenoglycosylation as a promising, germline-agnostic strategy for HIV-1 vaccine design. ONE-SENTENCE SUMMARY: Engineering the HIV-1 glycan shield with core α(1,3)-fucose promotes cross-clade neutralization
Open AccessXenoglycosylation of the HIV-1 Glycan Shield Promotes Cross-Clade Neutralization and Diverse Human Antibody Lineages
Despite advances in HIV-1 envelope glycoprotein (Env)-based vaccine design, eliciting broadly neutralizing antibodies (bNAbs) remains a central challenge. Here, we identify core α(1,3)-fucose as a key modulator of neutralizing antibody (NAb) induction and breadth. Uncleaved prefusion-optimized (UFO) trimers and self-assembling protein nanoparticles (SApNPs) produced in High Five (Hi5) insect cells incorporate core α(1,3)-fucose into the Env glycan shield. Crystal structures of Hi5-produced BG505 UFO trimers in complex with bNAbs confirm native-like Env architecture and epitope presentation. In wild-type mice, these trimers and SApNPs elicit robust autologous and heterologous NAb responses. We then engineer Chinese hamster ovary (CHO) cells to co-express three insect- and plant-derived core α(1,3)-fucosyltransferases. The resulting immunogens carry fucosylated mammalian glycans and elicit cross-clade NAb responses in mice, supporting an important role for core α(1,3)-fucose in broadened neutralization. Env-specific IgE responses suggest engagement of associated immune pathways during vaccination. In ATX-Gx humanized mice, core α(1,3)-fucosylated, glycan-trimmed Env elicits detectable cross-clade neutralization by week 11. Single-cell analysis identifies distinct human antibody lineages with cross-clade activity and noncanonical Env recognition. Repertoire and functional analyses uncover putatively related lineage members across two animals within the same group. Together, these findings support xenoglycosylation as a promising, germline-agnostic strategy for HIV-1 vaccine design. ONE-SENTENCE SUMMARY: Engineering the HIV-1 glycan shield with core α(1,3)-fucose promotes cross-clade neutralization
- Open Access
Programming N-linked glycan composition through de novo protein design
N-linked glycans are ubiquitous post-translational modifications that mediate diverse biological processes, including cell signaling and adhesion, molecular recognition, and host-pathogen interactions. Despite their importance, N-linked glycans have largely remained beyond the reach of biomolecular design due to a lack of methods capable of jointly modeling glycans and protein structure. Here, we develop a general all-atom computational pipeline for creating de novo glycoproteins in which the amino acid sequence encodes both the location and composition of N-linked glycans. The method uses three-dimensional protein structure to tune glycan accessibility to processing enzymes in the eukaryotic secretory pathway. Systematic increases in steric restriction progressively reduced processing, shifting glycans from heterogeneous complex-type structures toward increasingly underprocessed oligomannose-type species resembling those found on many viral glycoproteins. Despite this programmed restriction, the resulting oligomannose glycans remained accessible for biological recognition, inhibiting uropathogenic Escherichia coli adhesion to human bladder cells and binding mannose-binding lectin. These results establish steric control of N-glycan processing as a genetically encodable design principle and extend computational protein design to functional glycoproteins with programmed composition.
Open AccessProgramming N-linked glycan composition through de novo protein design
N-linked glycans are ubiquitous post-translational modifications that mediate diverse biological processes, including cell signaling and adhesion, molecular recognition, and host-pathogen interactions. Despite their importance, N-linked glycans have largely remained beyond the reach of biomolecular design due to a lack of methods capable of jointly modeling glycans and protein structure. Here, we develop a general all-atom computational pipeline for creating de novo glycoproteins in which the amino acid sequence encodes both the location and composition of N-linked glycans. The method uses three-dimensional protein structure to tune glycan accessibility to processing enzymes in the eukaryotic secretory pathway. Systematic increases in steric restriction progressively reduced processing, shifting glycans from heterogeneous complex-type structures toward increasingly underprocessed oligomannose-type species resembling those found on many viral glycoproteins. Despite this programmed restriction, the resulting oligomannose glycans remained accessible for biological recognition, inhibiting uropathogenic Escherichia coli adhesion to human bladder cells and binding mannose-binding lectin. These results establish steric control of N-glycan processing as a genetically encodable design principle and extend computational protein design to functional glycoproteins with programmed composition.
- Open Access
Extensive global HIV-1 sequence diversity perturbs conserved features of the envelope glycan shield
The extensive sequence diversity and glycosylation of the HIV-1 envelope glycoprotein pose a challenge for vaccine design efforts aimed at eliciting glycan-binding broadly neutralizing antibodies (bnAbs). Understanding how HIV-1 glycosylation varies across diverse strains is therefore of considerable interest. Here, we employed mass spectrometry to map the site-specific glycan composition of pseudoviruses from an established 12-virus panel representing global sequence diversity. We refine the current model of the viral glycan shield by showing how the presence or absence of glycans can modulate the composition and perimeter of the ‘mannose patch’, where glycans exhibit limited maturation. Importantly, we show that within the Clade A 398F1 strain, isolated in Tanzania, the trimer apex exhibited elevated glycan maturation and resistance to apex-directed bnAbs. These findings demonstrate that the 12-virus panel reveals both conserved glycan-dependent epitopes and strains with exceptional glycosylation features that may impact the generality of vaccine design efforts targeting particular epitopes. Highlights: Global HIV-1 diversity preserves key features of the envelope glycan shield Glycan occupancy and local networks reshape the perimeter of the mannose patch 398F1 displays atypical apex glycosylation linked to bnAb resistance Some glycan-dependent bnAb epitopes remain robust across diverse HIV-1 strains In Brief: Newby et al. map site-specific glycosylation across a globally representative 12-virus HIV-1 panel. Despite extensive sequence diversity, several glycan-dependent bnAb epitopes are conserved, while strain-specific differences in glycan occupancy and processing reveal features that may contribute to neutralization resistance.
Open AccessExtensive global HIV-1 sequence diversity perturbs conserved features of the envelope glycan shield
The extensive sequence diversity and glycosylation of the HIV-1 envelope glycoprotein pose a challenge for vaccine design efforts aimed at eliciting glycan-binding broadly neutralizing antibodies (bnAbs). Understanding how HIV-1 glycosylation varies across diverse strains is therefore of considerable interest. Here, we employed mass spectrometry to map the site-specific glycan composition of pseudoviruses from an established 12-virus panel representing global sequence diversity. We refine the current model of the viral glycan shield by showing how the presence or absence of glycans can modulate the composition and perimeter of the ‘mannose patch’, where glycans exhibit limited maturation. Importantly, we show that within the Clade A 398F1 strain, isolated in Tanzania, the trimer apex exhibited elevated glycan maturation and resistance to apex-directed bnAbs. These findings demonstrate that the 12-virus panel reveals both conserved glycan-dependent epitopes and strains with exceptional glycosylation features that may impact the generality of vaccine design efforts targeting particular epitopes. Highlights: Global HIV-1 diversity preserves key features of the envelope glycan shield Glycan occupancy and local networks reshape the perimeter of the mannose patch 398F1 displays atypical apex glycosylation linked to bnAb resistance Some glycan-dependent bnAb epitopes remain robust across diverse HIV-1 strains In Brief: Newby et al. map site-specific glycosylation across a globally representative 12-virus HIV-1 panel. Despite extensive sequence diversity, several glycan-dependent bnAb epitopes are conserved, while strain-specific differences in glycan occupancy and processing reveal features that may contribute to neutralization resistance.
- Open Access
- 13 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8335
Author Correction: Native-like soluble E1E2 glycoprotein heterodimers on self-assembling protein nanoparticles for hepatitis C virus vaccine design
- 13 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8335
Open AccessAuthor Correction: Native-like soluble E1E2 glycoprotein heterodimers on self-assembling protein nanoparticles for hepatitis C virus vaccine design
- Top Cited PapersOpen Access
- 18 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6804) , eaec6396
Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design
A major obstacle confronting HIV-1 vaccine and cure research is the lack of an outbred animal model for rapid and consistent induction of broadly neutralizing antibodies (bNAbs). We designed an epitope-focused simian-human immunodeficiency virus (SHIV.5MUT) that elicited broad and potent V3-glycan–targeted antibodies within a year of infection in 14 of 22 macaques compared with 0 of 14 control animals. SHIV.5MUT elicited bNAbs by a two-step mechanism, inducing an initial wave of V1-directed antibodies that selected for envelope (Env) glycoprotein variants with shortened, hypoglycosylated V1 loops, which in turn primed V3-glycan bNAb precursors. Rhesus bNAbs were immunogenetically and structurally diverse, closely resembling human V3-glycan bNAbs. Env-bNAb coevolution revealed a diverse repertoire of bNAb precursors and the Env variants that matured them, yielding a molecular blueprint for vaccine design.
- 18 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6804) , eaec6396
Top Cited PapersOpen AccessInduction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design
A major obstacle confronting HIV-1 vaccine and cure research is the lack of an outbred animal model for rapid and consistent induction of broadly neutralizing antibodies (bNAbs). We designed an epitope-focused simian-human immunodeficiency virus (SHIV.5MUT) that elicited broad and potent V3-glycan–targeted antibodies within a year of infection in 14 of 22 macaques compared with 0 of 14 control animals. SHIV.5MUT elicited bNAbs by a two-step mechanism, inducing an initial wave of V1-directed antibodies that selected for envelope (Env) glycoprotein variants with shortened, hypoglycosylated V1 loops, which in turn primed V3-glycan bNAb precursors. Rhesus bNAbs were immunogenetically and structurally diverse, closely resembling human V3-glycan bNAbs. Env-bNAb coevolution revealed a diverse repertoire of bNAb precursors and the Env variants that matured them, yielding a molecular blueprint for vaccine design.
- Open Access
Translating Innovation to Clinic: End-to-End Bioprocess Development and cGMP Manufacturing of N332-GT5 HIV Vaccine Candidate for First-in-Human Trials HVTN144
The successful translation of rationally designed HIV-1 immunogens into effective vaccines requires manufacturing platforms that maintain structural conformity while meeting clinical-grade quality standards. We developed and scaled a robust, cGMP-compliant process for N332-GT5 gp140, a germline-targeting envelope trimer designed to initiate broadly neutralizing antibody responses, which is now undergoing first-in-human evaluation in HVTN144. Starting with a stable CHO cell line developed using Leap-In® transposon technology, we established a production clone exhibiting high-titer expression (>200 mg/L) and genetic stability through 60 population doublings. The manufacturing process scaled efficiently from Ambr® 250 miniature bioreactors to 200-L single-use systems, delivering consistent product quality across multiple cGMP batches. A streamlined three-step purification strategy—affinity capture, multimodal polishing, and viral clearance- yielded >99% trimeric purity with preserved quaternary structure and native-like antigenicity. Orthogonal LC-MS analyses confirmed site-specific glycan occupancy matching design specifications, while robust viral clearance exceeded 18-log and 11-log reductions for model retroviruses. Clinical material manufactured through this platform has been successfully administered in HVTN144. This work establishes a scalable, reproducible manufacturing paradigm for structurally complex HIV-1 envelope immunogens, advancing the field toward rational vaccine design based on germline-targeting principles.
Open AccessTranslating Innovation to Clinic: End-to-End Bioprocess Development and cGMP Manufacturing of N332-GT5 HIV Vaccine Candidate for First-in-Human Trials HVTN144
The successful translation of rationally designed HIV-1 immunogens into effective vaccines requires manufacturing platforms that maintain structural conformity while meeting clinical-grade quality standards. We developed and scaled a robust, cGMP-compliant process for N332-GT5 gp140, a germline-targeting envelope trimer designed to initiate broadly neutralizing antibody responses, which is now undergoing first-in-human evaluation in HVTN144. Starting with a stable CHO cell line developed using Leap-In® transposon technology, we established a production clone exhibiting high-titer expression (>200 mg/L) and genetic stability through 60 population doublings. The manufacturing process scaled efficiently from Ambr® 250 miniature bioreactors to 200-L single-use systems, delivering consistent product quality across multiple cGMP batches. A streamlined three-step purification strategy—affinity capture, multimodal polishing, and viral clearance- yielded >99% trimeric purity with preserved quaternary structure and native-like antigenicity. Orthogonal LC-MS analyses confirmed site-specific glycan occupancy matching design specifications, while robust viral clearance exceeded 18-log and 11-log reductions for model retroviruses. Clinical material manufactured through this platform has been successfully administered in HVTN144. This work establishes a scalable, reproducible manufacturing paradigm for structurally complex HIV-1 envelope immunogens, advancing the field toward rational vaccine design based on germline-targeting principles.
- Open Access
- 8 June 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (24)
mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model
The unyielding antigenic drift of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as the threat of future zoonotic sarbecovirus spillovers, has prompted the search for broadly neutralizing antibodies (bNAbs) to inform rational therapeutic and vaccine design. Here, we isolated and characterized 20 receptor binding domain (RBD)-directed bNAb lineages from a serially sampled SARS-CoV-2 patient who was infected and vaccinated during the early months of the pandemic. Thirteen of these targeted the highly conserved, cryptic class 1/4 or class 4 RBD epitopes and had long (18 to 26 amino acid) heavy chain complementarity determining region 3 loops that utilized the IGHD3-22 gene segment. Five bNAbs potently neutralized all 18 viruses in a panel containing SARS-CoV-2 variants up to the recently emerged XBB.1.5 and JN.1 strains as well as diverse sarbecoviruses from other clades. Structural analyses of the Ab401 and Ab568 bNAbs complexed with RBD and Spike trimer, respectively, revealed recognition features in common with other class 1/4 bNAbs. Prophylactic administration of Ab401 as a recombinant protein afforded robust protection against infectious challenge with either SARS-CoV-2_WA1 or a related bat sarbecovirus with zoonotic potential. A similar level of protection was achieved when the heavy and light chains of Ab401 were delivered as lipid nanoparticle-encapsulated mRNAs. These data expand the arsenal of SARS-CoV-2 bNAbs for clinical development and identify mRNA-based antibody delivery as a promising platform for both pandemic preparedness and protection of immunocompromised patients against emerging sarbecovirus variants.
- 8 June 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (24)
Open AccessmRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model
The unyielding antigenic drift of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as the threat of future zoonotic sarbecovirus spillovers, has prompted the search for broadly neutralizing antibodies (bNAbs) to inform rational therapeutic and vaccine design. Here, we isolated and characterized 20 receptor binding domain (RBD)-directed bNAb lineages from a serially sampled SARS-CoV-2 patient who was infected and vaccinated during the early months of the pandemic. Thirteen of these targeted the highly conserved, cryptic class 1/4 or class 4 RBD epitopes and had long (18 to 26 amino acid) heavy chain complementarity determining region 3 loops that utilized the IGHD3-22 gene segment. Five bNAbs potently neutralized all 18 viruses in a panel containing SARS-CoV-2 variants up to the recently emerged XBB.1.5 and JN.1 strains as well as diverse sarbecoviruses from other clades. Structural analyses of the Ab401 and Ab568 bNAbs complexed with RBD and Spike trimer, respectively, revealed recognition features in common with other class 1/4 bNAbs. Prophylactic administration of Ab401 as a recombinant protein afforded robust protection against infectious challenge with either SARS-CoV-2_WA1 or a related bat sarbecovirus with zoonotic potential. A similar level of protection was achieved when the heavy and light chains of Ab401 were delivered as lipid nanoparticle-encapsulated mRNAs. These data expand the arsenal of SARS-CoV-2 bNAbs for clinical development and identify mRNA-based antibody delivery as a promising platform for both pandemic preparedness and protection of immunocompromised patients against emerging sarbecovirus variants.